Tralokinumab-induced injection-site reactions

Axel De Greef^{1

2}, Marie Baeck^{1

2}

Affiliations

¹ Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
² Institute of Experimental and Clinical Research (IREC), Pneumology, ENT and Dermatology Pole (LUNS), Université catholique de Louvain (UCLouvain), Brussels, Belgium.

Case Reports

Axel De Greef et al. Contact Dermatitis. 2024 Dec.

. 2024 Dec;91(6):521-522.

doi: 10.1111/cod.14671. Epub 2024 Aug 11.

Axel De Greef^{1

2}, Marie Baeck^{1

2}

¹ Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
² Institute of Experimental and Clinical Research (IREC), Pneumology, ENT and Dermatology Pole (LUNS), Université catholique de Louvain (UCLouvain), Brussels, Belgium.

No abstract available

Keywords: adverse drug reaction; atopic dermatitis; injection site reaction; skin test; tralokinumab.

References

1. Paller AS, Flohr C, Cork M, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159(6):596‐605.
1. Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450‐463.
1. De Greef A, Ghislain PD, Bulinckx A, et al. Real‐life experience of tralokinumab for the treatment of adult patients with severe atopic dermatitis: a multicentric prospective study. Clin Drug Investig. 2023;43(4):299‐306.
1. De Greef A, Ghislain PD, de Montjoye L, et al. Tralokinumab improves clinical scores in adolescents with severe atopic dermatitis: a real‐life multicentric observational study. J Eur Acad Dermatol Venereol. 2024;38(3):e288‐e290.
1. Martora F, Patruno C, D'Ascenzo S, Napolitano M. Injection site reactions after dupilumab or tralokinumab for atopic dermatitis. J Dermatolog Treat. 2024;35(1):2304027.